SILO

Silo Pharma (SILO)

Silo Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SILO

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/14	06 : 08	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:SILO	Silo Pharma Inc
2024/06/14	02 : 19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SILO	Silo Pharma Inc
2024/06/12	05 : 00	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:SILO	Silo Pharma Inc
2024/06/07	21 : 18	GlobeNewswire Inc.	Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia	NASDAQ:SILO	Silo Pharma Inc
2024/06/07	05 : 52	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SILO	Silo Pharma Inc
2024/06/07	05 : 50	GlobeNewswire Inc.	Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	NASDAQ:SILO	Silo Pharma Inc
2024/06/06	19 : 07	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:SILO	Silo Pharma Inc
2024/06/05	21 : 00	GlobeNewswire Inc.	Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	NASDAQ:SILO	Silo Pharma Inc
2024/06/05	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SILO	Silo Pharma Inc
2024/06/04	21 : 41	GlobeNewswire Inc.	Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety	NASDAQ:SILO	Silo Pharma Inc
2024/05/21	21 : 45	GlobeNewswire Inc.	Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention	NASDAQ:SILO	Silo Pharma Inc
2024/05/14	21 : 45	GlobeNewswire Inc.	Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine	NASDAQ:SILO	Silo Pharma Inc
2024/05/14	05 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SILO	Silo Pharma Inc
2024/04/23	21 : 15	GlobeNewswire Inc.	Silo Pharma Announces Positive Results for Intranasal PTSD Treatment	NASDAQ:SILO	Silo Pharma Inc
2024/04/10	21 : 11	GlobeNewswire Inc.	Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic	NASDAQ:SILO	Silo Pharma Inc
2024/03/20	21 : 30	GlobeNewswire Inc.	Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic	NASDAQ:SILO	Silo Pharma Inc
2024/03/18	20 : 15	GlobeNewswire Inc.	Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	NASDAQ:SILO	Silo Pharma Inc
2024/02/28	22 : 25	GlobeNewswire Inc.	Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD	NASDAQ:SILO	Silo Pharma Inc
2024/02/14	22 : 45	GlobeNewswire Inc.	Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	NASDAQ:SILO	Silo Pharma Inc
2024/02/02	03 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SILO	Silo Pharma Inc
2024/02/02	00 : 00	GlobeNewswire Inc.	Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	NASDAQ:SILO	Silo Pharma Inc
2024/01/31	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SILO	Silo Pharma Inc
2024/01/26	07 : 29	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:SILO	Silo Pharma Inc
2024/01/26	07 : 27	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SILO	Silo Pharma Inc
2024/01/24	22 : 55	GlobeNewswire Inc.	Silo Pharma Announces Positive Results in Alzheimer’s Disease Study	NASDAQ:SILO	Silo Pharma Inc
2024/01/24	07 : 01	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:SILO	Silo Pharma Inc
2024/01/12	02 : 15	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:SILO	Silo Pharma Inc
2024/01/10	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SILO	Silo Pharma Inc
2024/01/04	22 : 55	GlobeNewswire Inc.	Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	NASDAQ:SILO	Silo Pharma Inc
2023/12/28	22 : 25	GlobeNewswire Inc.	Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	NASDAQ:SILO	Silo Pharma Inc